<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
  <title>GIDS Research Radar · Sudan</title>
  <link>https://globalinfectiousdisease.com/research/</link>
  <description>Published infectious-disease literature filtered to Sudan.</description>
  <language>en</language>
  <atom:link href="https://globalinfectiousdisease.com/research/rss/countries/sd.xml" rel="self" type="application/rss+xml" />
  <lastBuildDate>Wed, 09 Sep 2026 07:02:01 GMT</lastBuildDate>
  <item>
    <title>Implementing an intra outbreak ring vaccination clinical trial for Sudan Ebola virus disease within four days of outbreak notification in Uganda.</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1080-22221751-2026-2731496-7d1abb29/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1080-22221751-2026-2731496-7d1abb29/</guid>
    <pubDate>Mon, 07 Sep 2026 00:00:00 GMT</pubDate>
    <description>The four-day turnaround provides a replicable blueprint for rapid medical countermeasure evaluation during future outbreaks in settings with heightened Ebola Virus Disease threat. The approach demonstrates that prepositioned protocols, established infrastructure, and trained personnel can dramatically compress trial activation timelines.</description>
    <category>Ebola</category>
    <category>Vaccination</category>
    <category>Outbreak investigation</category>
    <category>Treatment</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Tuberculosis-related knowledge, attitudes, and self-reported preventive practices among medical students at the University of Khartoum: A cross-sectional educational survey.</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1371-journal-pone-0357003-3d2144fc/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1371-journal-pone-0357003-3d2144fc/</guid>
    <pubDate>Tue, 25 Aug 2026 00:00:00 GMT</pubDate>
    <description>The findings identify specific TB knowledge gaps among future clinicians in a high-burden setting and may inform curricular reinforcement of TB-related knowledge, attitudes, and preventive practices.</description>
    <category>Tuberculosis</category>
    <category>Transmission dynamics</category>
    <category>Cross-sectional study</category>
  </item>
  <item>
    <title>From visceral to visible: A systematic review and meta-analysis of post-kala-azar dermal leishmaniasis incidence, risk factors, and treatment outcomes in Eastern Africa</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1371-journal-pntd-0014666-afa1362a/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1371-journal-pntd-0014666-afa1362a/</guid>
    <pubDate>Tue, 18 Aug 2026 00:00:00 GMT</pubDate>
    <description>Consolidating regional outcome data helps identify modifiable therapeutic variables and highlights gaps in longitudinal tracking necessary for coordinated control initiatives.</description>
    <category>Kala-azar</category>
    <category>Leishmaniasis</category>
    <category>Treatment</category>
    <category>Surveillance</category>
    <category>Transmission dynamics</category>
    <category>Systematic review</category>
  </item>
  <item>
    <title>PEMBERANTASAN SARANG NYAMUK (PSN) - DEMAM BERDARAH DENGUE (DBD) DI DESA BANING KOTA DAN JERORA, SINTANG (Implementation of Mosquito Nest Eradication - Dengue Hemorrhagic Fever)</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-29103-uhjpm-v2i1-15193-e8906bcb/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-29103-uhjpm-v2i1-15193-e8906bcb/</guid>
    <pubDate>Sat, 15 Aug 2026 00:00:00 GMT</pubDate>
    <description>Sustained vector management requires ongoing community education and multi-agency cooperation to maintain environmental hygiene and interrupt pathogen spread cycles.</description>
    <category>Hemorrhagic Fever</category>
    <category>Dengue</category>
    <category>Surveillance</category>
    <category>Transmission dynamics</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Pan-Ebolavirus nanoparticle vaccine provides protection in rodents from lethal infection by Zaire and Sudan viruses</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1038-s41467-026-76114-1-dbca88c1/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1038-s41467-026-76114-1-dbca88c1/</guid>
    <pubDate>Sat, 08 Aug 2026 00:00:00 GMT</pubDate>
    <description>Findings support continued development of a pan-ebolavirus vaccine built on the I53-50 platform, which has established clinical safety, and may be relevant for populations at risk of EBOV and SUDV outbreaks.</description>
    <category>Hemorrhagic Fever</category>
    <category>Ebola</category>
    <category>Vaccination</category>
    <category>Outbreak investigation</category>
    <category>One Health</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Willingness to receive Ebola vaccines among pregnant and lactating women in Kampala, Uganda: insights from a post-outbreak cross-sectional study</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128737-43c54279/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128737-43c54279/</guid>
    <pubDate>Mon, 01 Jun 2026 00:00:00 GMT</pubDate>
    <description>Results underscore the necessity of incorporating maternal populations into emergency immunization protocols while simultaneously deploying targeted educational initiatives to mitigate safety concerns and knowledge deficits.</description>
    <category>Ebola</category>
    <category>COVID-19</category>
    <category>Hemorrhagic Fever</category>
    <category>Vaccination</category>
    <category>Outbreak investigation</category>
    <category>Climate and environment</category>
    <category>Cross-sectional study</category>
  </item>
  <item>
    <title>Risk factors for post-kala-azar dermal leishmaniasis (PKDL): Challenges in understanding pathophysiology</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1371-journal-pntd-0013952-7b81c20d/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1371-journal-pntd-0013952-7b81c20d/</guid>
    <pubDate>Mon, 23 Feb 2026 00:00:00 GMT</pubDate>
    <description>The authors emphasize the need to integrate PKDL management within broader skin disease programs and to optimize VL treatment (e.g., multidrug regimens, immune modifiers) to potentially reduce PKDL incidence.</description>
    <category>Leishmaniasis</category>
    <category>Kala-azar</category>
    <category>Treatment</category>
    <category>Climate and environment</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Investigating the Sudan virus outbreak in Uganda through the deployment of a mobile laboratory</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1186-s12879-026-12556-8-67e9ba93/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1186-s12879-026-12556-8-67e9ba93/</guid>
    <pubDate>Fri, 16 Jan 2026 00:00:00 GMT</pubDate>
    <description>Co-locating a mobile laboratory with the treatment unit shortened diagnostic turnaround, supported national data-driven decision-making, and enabled follow-up surveillance relevant to outbreak containment and survivor counselling.</description>
    <category>Ebola</category>
    <category>Hemorrhagic Fever</category>
    <category>Rift Valley fever</category>
    <category>Outbreak investigation</category>
    <category>Surveillance</category>
    <category>Diagnostics</category>
    <category>Treatment</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Sudan virus disease outbreak in Uganda: urgent research gaps</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1136-bmjgh-2022-010982-b4e8d0a7/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1136-bmjgh-2022-010982-b4e8d0a7/</guid>
    <pubDate>Fri, 30 Dec 2022 00:00:00 GMT</pubDate>
    <description>The authors highlight limited SUDV research investment, no licensed vaccine or therapeutics, ongoing transmission across regions of Uganda including the capital, and an uncertain case count as drivers of concern.</description>
    <category>Ebola</category>
    <category>Hemorrhagic Fever</category>
    <category>COVID-19</category>
    <category>Outbreak investigation</category>
    <category>Transmission dynamics</category>
    <category>Vaccination</category>
    <category>Treatment</category>
    <category>One Health</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Louse-borne relapsing fever (Borrelia recurrentis) diagnosed in 15 refugees from northeast Africa: epidemiology and preventive control measures, Bavaria, Germany, July to October 2015</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-2807-1560-7917-es-2015-20-42-30046-aa85d151/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-2807-1560-7917-es-2015-20-42-30046-aa85d151/</guid>
    <pubDate>Thu, 22 Oct 2015 00:00:00 GMT</pubDate>
    <description>The report highlights the need for clinicians caring for refugees traversing north Africa to recognise louse-borne relapsing fever, in order to provide timely treatment and apply preventive measures.</description>
    <category>Relapsing fever</category>
    <category>Treatment</category>
    <category>Travel medicine</category>
    <category>Climate and environment</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1016-s0140-6736-14-62385-0-38ad575b/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1016-s0140-6736-14-62385-0-38ad575b/</guid>
    <pubDate>Wed, 01 Apr 2015 00:00:00 GMT</pubDate>
    <description>The paper is relevant to vaccine development for two high-fatality viral diseases and to early clinical evaluation of candidate vaccines in an African setting. It also provides context for later development work on Ebola vaccine antigens.</description>
    <category>Ebola</category>
    <category>Treatment</category>
    <category>Vaccination</category>
    <category>Outbreak investigation</category>
    <category>Randomised controlled trial</category>
  </item>
</channel>
</rss>
